ANIP SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 7, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Feb 27, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 7, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

ANI Pharmaceuticals Considering Voluntary Public Offer for Egetis Therapeutics AB

Nov 5, 2026

8-K

ANI Pharmaceuticals Reports Q3 2026 Results and Proposed Acquisition of Egetis Therapeutics

Nov 5, 2026

8-K

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors

Aug 24, 2026

8-K

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Aug 7, 2026

8-K

ANI Pharmaceuticals, Inc. Announces Results of 2026 Annual Meeting of Stockholders

May 21, 2026

8-K

ANI Pharmaceuticals, Inc. May 2026 Corporate Presentation and Financial Guidance Update

May 13, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B5

SHELF OFFERING | Shares amount: 1,898,735 | Share price: $39.50 | Offering amount: $75,000,032.50 | Bank: Guggenheim Securities, Truist Securities, H.C. Wainwright & Co.

May 12, 2023

424B5

PENDING OFFERING | Bank: Guggenheim Securities

May 11, 2023

424B3

3,069,555 Shares-

Jan 19, 2022

424B5

1,500,000 Shares-

Nov 4, 2021

424B5

Common Stock-

Nov 3, 2021

424B5

Form 424B5 - Prospectus [Rule 424(b)(5)]

Dec 5, 2014

Registrations

TYPE

HEADLINE

FILED AT

S-8